

Boston Scientific Begins Expansion of The S-ICD™ System in Asia

NATICK, Mass., April 7, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has expanded the launch of its S-ICD System into parts of Asia. The first implant of the S-ICD System in Asia was performed in Hong Kong by Prof. Hung Fat Tse, Professor of Cardiovascular Medicine, The University of Hong Kong and Department of Medicine, Queen Mary Hospital in Pokfulam, Hong Kong, under the proctorship of Dr. Martin Stiles, Director of Electrophysiology, Waikato Hospital in Hamilton, New Zealand.

Recent estimates show that almost 2 million people in Asia Pacific are at risk of sudden cardiac arrest (SCA) but are currently unprotected^{[(i)],[(ii)],[(iii)],[(iv)]}. As the world's least invasive implantable defibrillator, the S-ICD System provides protection for patients at risk of sudden cardiac arrest, leaving the heart and blood vessels untouched, and offering patients a compelling alternative to transvenous implantable cardioverter defibrillators (TV-ICDs), which require leads to be placed in the heart. Implantation of the S-ICD System uses anatomical landmarks without the need for fluoroscopy.*

"The S-ICD System is a revolutionary and unique option for patients at risk of SCA," said Prof. Hung Fat Tse. "I envision the S-ICD System to be the first choice solution for eligible patients because it provides a less invasive therapy with performance as good as TV-ICDs."

This breakthrough defibrillation therapy has been commercially available in Europe since 2009 and was approved in the United States in late 2012. Boston Scientific continues to expand the availability of this unique therapy for patients and physicians around the world.

"Most of the world's population resides in Asia, which includes a high portion of unprotected patients at risk of SCA. The S-ICD System highlights Boston Scientific's commitment to bring meaningful innovation to patients and physicians in this critically important region," said Supratim Bose, Executive Vice President and President, Asia, Middle-East and Africa, Boston Scientific.

The S-ICD does not have regulatory approval in China, Japan or South Korea and is not available for sale in those countries.

*Fluoroscopy is required for implanting the leads attached to TV-ICDs

About Boston Scientific

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on [Twitter](#) and [Facebook](#).

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding markets for our products, our business plans, product launches, product performance and impact, and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – *Risk Factors* in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – *Risk Factors* in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT:
Nisha Deo

508-652-5609 (office)
Corporate Affairs & Communications
Boston Scientific Corporation
Nisha.Deo@bsci.com

Susie Lisa, CFA
508-652-5345 (office)
Investor Relations
Boston Scientific Corporation
investor_relations@bsci.com

[i] Alessandra Doolan, Neil Langlois and Christopher Semsarian, Causes of sudden cardiac death in young Australians, Medical Journal of Australia MJA 2004; 180 (3): 110-112

[ii] Minako Maruyama, Tetsuya Ohira, Hironori Imano, Akihiko Kitamura, Masahiko Kiyama, Takeo Okada, Kenji Maeda, Kazumasa Yamagishi, Hiroyuki Noda, Yoshinori Ishikawa, Takashi Shimamoto, and Hiroyasu Iso, [Trends in sudden cardiac death and its risk factors in Japan from 1981 to 2005: the Circulatory Risk in Communities Study \(CIRCS\)](#) BMJ Open. 2012; 2(2): e000573

[iii] Zhang Shu, [Sudden cardiac death in China](#), Pacing Clin Electrophysiol. 2009 Sep;32(9):1159-62. doi: 10.1111/j.1540-8159.2009.02458.x.

[iv] Murakoshi N and Aonuma K, [Epidemiology of arrhythmias and sudden cardiac death in Asia](#), Circ J. 2013;77(10):2419-31. Epub 2013 Sep 20.

SOURCE Boston Scientific Corporation

<https://news.bostonscientific.com/2014-04-07-Boston-Scientific-Begins-Expansion-of-The-S-ICD-System-in-Asia>